
Innovative Oligonucleotide Strategies for Targeted RNA Expression Modulation

Daiichi Sankyo, a global pharmaceutical company, is seeking novel **oligonucleotide-based approaches** to efficiently and specifically **increase or decrease target RNAs** both *in vitro* and *in vivo* for developing new treatments. Additionally, cutting-edge **RNA editing techniques** are also of interest.



Approaches of Interest:

- Novel oligonucleotide-based technology that can control RNA expression levels or change RNA sequences e.g., dual-targeting antisense oligonucleotides (ASOs) and advanced RNA editing technologies
- Novel technologies for efficient transport from extracellular space into cytosol, nucleus or mitochondria e.g., chemically
 modified oligonucleotides to enhance transport from the cytosol into the nucleus
- · Novel target-identification methods for oligonucleotide-based approaches such as ASO and RNA editing
- Research findings on novel biological regulatory pathways or molecules that control RNA transcription, splicing, translation, or transport, with potential for future development as described in the previous three bullet points
 - Opportunities should demonstrate how the newly identified RNA targets could contribute to treating specific diseases

Out of Scope:

- Packaging technologies/delivery systems (e.g. viral vectors, nanoparticles)
- For submissions relating to ASOs, RNA editing techniques, and conventional technologies that modulate RNA by endogenous Ago2, RNase H or ADAR are out of scope
- · Submissions based on hypothetical ideas or lacking sufficient proof-of-concept

Developmental Stages of Interest:

• Submissions must include, at minimum, in vitro data; in vivo data is preferred

Submission Information

Submission of one-page, 200–300-word briefs is encouraged, along with any optional supplementary information e.g. relevant publications. **Our client is also open to novel research proposals which can be outlined using this submission form.** In submitting to this campaign, you confirm that your submission contains only non-confidential information.

Opportunity for Collaboration

Our client is open to a range of collaboration opportunities, with the most appropriate outcome being decided on a case-by-case basis. Example outcomes include licensing assets, project/PhD funding, and research collaborations.

Opportunities sought



Technologies

Centres of excellence

Research projects

Spinout companies

Submissions

Please submit relevant, non-confidential opportunities online here

Deadline: 2nd February 2026 - 11:59 pm GMT

Have any questions?
Contact our team at discover@in-part.co.uk



Daiichi Sankyo is focused on enriching the quality of life around the world by creating innovative pharmaceuticals to address diverse medical needs.